A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for ...

Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...